By Graphene Leaders Canada Inc.
GLC Medical (GLCM) Inc., the medical subsidiary of Graphene Leaders Canada, has developed a breakthrough biosensor platform that delivers pathogen detection in under one minute, utilizing advanced electrochemical impedance spectroscopy (EIS) technology. Originally developed for rapid COVID-19 detection, the GLCM platform has been validated by the Alberta Health Services Provincial Testing Centre, the University of Alberta’s Li Ka Shing Institute of Virology, and the University of Sherbrooke. The platform is adaptable for multiple pathogens, offering a fast, reliable, and highly accurate testing solution for pandemic, endemic, and epidemic preparedness. Building on its diagnostic foundation, GLCM has expanded the platform’s capabilities to target real-time environmental monitoring, enabling detection of heavy metal ions and waterborne pathogens for water quality assessment in a wide range of field and industrial settings. This innovative technology is poised to transform traditional diagnostics by delivering a portable, rapid, highly accurate, reliable and versatile detection solution that supports public health, environmental safety, and global preparedness efforts.
